PD-1 regulates extrathymic regulatory T-cell differentiation
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Treg cells and the programed death-1/programed death ligand-1 (PD-1/PD-L1) pathway are both critical for maintaining peripheral tolerance to self-Ags. A significant subset of Treg cells constitutively expresses PD-1, which prompted an investigation into the role of PD-1/PD-L1 interactions in Treg-cell development, function, and induction in vivo. The phenotype and abundance of Treg cells was not significantly altered in PD-1-deficient mice. The thymic development of polyclonal and monospecific Treg cells was not negatively impacted by PD-1 deficiency. The suppressive function of PD-1(-/-) Treg cells was similar to their PD-1(+/+) counterparts both in vitro and in vivo. However, in three different in vivo experimental settings, PD-1(-/-) conventional CD4(+) T cells demonstrated a strikingly diminished tendency toward differentiation into peripherally induced Treg (pTreg) cells. Our results demonstrate that PD-1 is dispensable for thymic Treg-cell development and suppressive function, but is critical for the extrathymic differentiation of pTreg cells in vivo. These data suggest that Ab blockade of the PD-1/PD-L1 pathway may augment T-cell responses by acting directly on conventional T cells, and also by suppressing the differentiation of pTreg cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The PD-1/PD-L1 blockade pathway increases T-cell response via Treg differentiation (116).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Cited by
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
T cell metabolic fitness in antitumor immunity
Siska, P. J., & Rathmell, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.007 · Cited by 312
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 236
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 218
Kumar, P., Bhattacharya, P., & Prabhakar, B. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.007 · Cited by 216
Metabolic Barriers to T Cell Function in Tumors
Sugiura, A., & Rathmell, J. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701041 · Cited by 208
“Additionally, PD-1 ligation has been shown to promote FAO (7), thereby promoting Treg cell differentiation and suppressive activity (81) as well as Tmem cell formation (82) as shown by murine adoptive transfer studies.”
BackgroundFerris, R. L., Lenz, H.-J., Trotta, A. M., García-Foncillas, J., Schulten, J., Audhuy, F., Merlano, M., & Milano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.008 · Cited by 190
The immune microenvironment in gastric adenocarcinoma
Zavros, Y., & Merchant, J. L. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00591-0 · Cited by 188
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
Massari, F., Santoni, M., Ciccarese, C., Santini, D., Alfieri, S., Martignoni, G., Brunelli, M., Piva, F., Berardi, R., Montironi, R., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.013 · Cited by 180
Siska, P. J., van der Windt, G. J. W., Kishton, R. J., Cohen, S., Eisner, W., MacIver, N. J., Kater, A. P., Weinberg, J. B., & Rathmell, J. C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502464 · Cited by 151
Phenotypical characterization of regulatory T cells in humans and rodents
Rodríguez-Perea, A. L., Arcia, E. D., Rueda, C. M., & Velilla, P. A. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12804 · Cited by 166
Hu, B., Lin, J., Yang, X., & Sang, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12772 · Cited by 164
Dawson, N. A. J., Rosado-Sánchez, I., Novakovsky, G. E., Fung, V. C. W., Huang, Q., McIver, E., Sun, G., Gillies, J., Speck, M., Orban, P. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3866 · Cited by 147
de Coaña, Y. P., Wolodarski, M., Poschke, I., Yoshimoto, Y., Yang, Y., Nyström, M., Edbäck, U., Brage, S. E., Lundqvist, A., Masucci, G. V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15368 · Cited by 139
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer
Chakrabarti, J., Holokai, L., Syu, L., Steele, N. G., Chang, J., Wang, J., Ahmed, S., Dlugosz, A., & Zavros, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.26473 · Cited by 138
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
DiDomenico, J., Lamano, J. B., Oyon, D., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 115
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Mechanisms of human FoxP3+ Treg cell development and function in health and disease
Attias, M., Al-Aubodah, T.-A., & Piccirillo, C. A. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13290 · Cited by 114
Holokai, L., Chakrabarti, J., Lundy, J., Croagh, D., Adhikary, P., Richards, S. S., Woodson, C., Steele, N., Kuester, R., Scott, A., et al. (2020) · Cancers · doi:10.3390/cancers12123816 · Cited by 110
Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node
Alonso, R., Flament, H., Lemoine, S., Sedlik, C., Bottasso, E., Péguillet, I., Prémel, V., Denizeau, J., Salou, M., Darbois, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04524-x · Cited by 101
Regulatory T cells in skeletal muscle repair and regeneration: recent insights
Wu, J., Ren, B., Wang, D., & Lin, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05142-8 · Cited by 110
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 109
Scheff, N. N., Ye, Y., Bhattacharya, A., MacRae, J., Hickman, D. N., Sharma, A. K., Dolan, J. C., & Schmidt, B. L. (2017) · Pain · doi:10.1097/j.pain.0000000000001044 · Cited by 107
Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells
Zavros, Y. L. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.03.003 · Cited by 106
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy
Horton, J. D., Knochelmann, H. M., Day, T. A., Paulos, C. M., & Neskey, D. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.007 · Cited by 103
Perry, J. A., Shallberg, L., Clark, J. T., Gullicksrud, J. A., DeLong, J. H., Douglas, B. B., Hart, A. P., Lanzar, Z., O’Dea, K., Konradt, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01170-w · Cited by 101
Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy
Жулай, Г. А., & Олейник, Е. К. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13129 · Cited by 100
Kim, M. J., Kim, K., Park, H. J., Kim, G.-R., Hong, K. H., Oh, J. H., Son, J., Park, D. J., Kim, D., Choi, J.-M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01373-1 · Cited by 90
Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells
Bourque, J., & Hawiger, D. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026790 · Cited by 81
Schultz, K. R., Kariminia, A., Ng, B., Abdossamadi, S., Lauener, M. P., Nemecek, E. R., Wahlstrom, J. T., Kitko, C. L., Lewis, V. A., Schechter, T., et al. (2020) · Blood · doi:10.1182/blood.2019003186 · Cited by 73
Köstlin, N., Vogelmann, M., Spring, B., Schwarz, J., Feucht, J., Härtel, C., Orlikowsky, T. W., Poets, C. F., & Gille, C. (2017) · Immunology · doi:10.1111/imm.12751 · Cited by 68
Toxicity Patterns With Immunomodulating Antibodies and Their Combinations
Haanen, J. B. A. G., van Thienen, J. V., & Blank, C. U. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.011 · Cited by 64
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 60
Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Xie, M., Wei, J., & Xu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00676 · Cited by 60
Chakrabarti, J. L., Koh, V., Steele, N. G., Hawkins, J., Ito, Y., Merchant, J. L., Wang, J., Helmrath, M. A., Ahmad, S. A., So, J. B. Y., et al. (2021) · Cancers · doi:10.3390/cancers13246158 · Cited by 57
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Harjunpää, H., Blake, S. J., Ahern, E. S., Allen, S. M., Liu, J., Yan, J., Lutzky, V. P., Takeda, K., Aguilera, A. R., Guillerey, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445949 · Cited by 52
Walankiewicz, M., Grywalska, E., Polak, G., Korona‐Głowniak, I., Witt, E., Surdacka, A., Kotarski, J., & Roliński, J. (2018) · Mediators of Inflammation · doi:10.1155/2018/7041342 · Cited by 51
RORγt Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells
Bhaumik, S., Mickael, M., Moran, M., Spell, M. L., & Basu, R. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100175 · Cited by 48
Kos, K., Salvagno, C., Wellenstein, M. D., Aslam, M. A., Meijer, D. A., Hau, C., Vrijland, K., Kaldenbach, D., Raeven, E. A. M., Schmittnaegel, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2063225 · Cited by 47
Ellestad, K. K., Thangavelu, G., Ewen, C., Boon, L., & Anderson, C. C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444688 · Cited by 47
Suzuki, S., Ogawa, T., Sano, R., Takahara, T., Inukai, D., Satou, A., Tsuchida, H., Yoshikawa, K., Ueda, R., & Tsuzuki, T. (2020) · Cancer Science · doi:10.1111/cas.14422 · Cited by 46
Zhao, Y., Zhang, X., Du, N., Sun, H., Chen, L., Bao, H., Zhao, Q., Qu, Q., Ma, D., Kwak-Kim, J. Y.-H., et al. (2020) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2020.103208 · Cited by 43
Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 41
Li, L., Yang, S., Yao, Y., Xie, Y., Yang, Y., Wang, Y., Yin, X., Ma, H., Gershwin, M., & Lian, Z. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.348 · Cited by 40
Liu, Q., An, L., Qi, Z., Zhao, Y., & Li, C. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12612 · Cited by 36
Yero, A., Shi, T., Farnós, O., Routy, J., Tremblay, C. L., Durand, M., Tsoukas, C. M., Costiniuk, C. T., & Jenabian, M.-A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103570 · Cited by 34
Zhou, J., Li, J., Chen, J., Lan, X., Ai, Y., Liu, P., Peng, J., Pan, X., Zhang, Y., Zhang, H., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115191 · Cited by 33
Hollander, P., Rostgaard, K., Smedby, K. E. E., Molin, D. L., Loskog, A., Brown, P. D. N., Enblad, G., Amini, R., Hjalgrim, H., & Glimelius, I. C. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12987 · Cited by 33
PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma
Lim, J. X., McTaggart, T., Jung, S. K., Smith, K. J., Hulme, G., Laba, S., Ng, Y. Q., Williams, A., Hussain, R., Coxhead, J., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02172-0 · Cited by 32
The emerging role of tissue regulatory T cells in tissue repair and regeneration
Raheem, A., Khan, I., Ahmad, I., Wajid, A., Alshahrani, M. Y., Alzahrani, F. M., Alzahrani, K. J., Qadeer, A., Liao, I., & Chen, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640113 · Cited by 30
Cuvelier, G. D. E., Li, A., Drissler, S., Kariminia, A., Abdossamadi, S., Rozmus, J., Chanoine, J., Ng, B., Mostafavi, S., Brinkman, R. R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571884 · Cited by 28
Zhao, Z., Zhang, X., Su, L., Xu, L., Zheng, Y., & Sun, J. M. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.01.042 · Cited by 27
Neuroinflammation: Extinguishing a blaze of T cells
Benallegue, N., Kébir, H., & Alvarez, J. I. (2022) · Immunological Reviews · doi:10.1111/imr.13122 · Cited by 26
Nanomaterials for antigen-specific immune tolerance therapy
Park, J.-W., Wu, Y., Li, Q., Choi, J., Ju, H., Cai, Y., Lee, J., & Oh, Y. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01233-3 · Cited by 26
Verhagen, J., Wegner, A., & Wraith, D. C. (2015) · Immunology · doi:10.1111/imm.12458 · Cited by 25
Association of PDCD1 gene markers with susceptibility to thyroid cancer
Haghshenas, M. R., Dabbaghmanesh, M. H., Miri, A., Ghaderi, A. A., & Erfani, N. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0579-5 · Cited by 25
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
Taylor, J. G., Truelove, E., Clear, A. J., Calaminici, M., & Gribben, J. G. (2022) · Haematologica · doi:10.3324/haematol.2022.280014 · Cited by 23
Nair, V. S., Toor, S. M., Taouk, G. M., Pfister, G., Ouararhni, K., Alajez, N. M., & Elkord, E. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900575 · Cited by 23
Chen, P., Mamillapalli, R., Habata, S., & Taylor, H. S. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-04012-1 · Cited by 23
Regulatory Rebound in IL-12–Treated Tumors Is Driven by Uncommitted Peripheral Regulatory T Cells
Li, Q., Virtuoso, L. P., Anderson, C. D., & Egilmez, N. K. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403078 · Cited by 22
Levingston, C. A., & Young, M. R. (2016) · International Journal of Cancer · doi:10.1002/ijc.30543 · Cited by 21
The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
Grywalska, E., Smarz-Widelska, I., Krasowska-Zajac, E., Korona‐Głowniak, I., Załuska-Patel, K., Mielnik, M., Podgajna, M., Malm, A., Roliński, J., & Zaluska, W. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0485-3 · Cited by 18
Voynova, E., Mahmoud, T. I., Woods, L. T., Weisman, G. A., Ettinger, R., & Braley‐Mullen, H. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1700069 · Cited by 18
PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma
Curran, C. S., & Sharon, E. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.12.001 · Cited by 17
MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma
Malpeli, G., Barbi, S., Greco, C., Zupo, S., Bertolaso, A., Scupoli, M. T., Krampera, M., Kamga, P. T., Croce, C. M., Scarpa, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24987 · Cited by 16
Tomaszewski, M., Grywalska, E., Tomaszewski, A. J., Błaszczak, P., Kurzyna, M., Roliński, J., & Kopeć, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061966 · Cited by 16
Shou, J., Shi, X., Liu, X., Chen, Y., Chen, P., & Xiao, W. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00542-4 · Cited by 14
Qi, Z., Liu, Q., Zhang, Q., Liu, B., & Li, C. (2018) · Resuscitation · doi:10.1016/j.resuscitation.2018.06.023 · Cited by 14
Gu, W., Ge, R., Zhu, F., Li, D., Liang, R., Ge, J., Wang, Y., Li, B., & Qiu, J. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153021 · Cited by 13
Loacker, L., Egger, A., Fux, V., Bellmann‐Weiler, R., Weiß, G., Griesmacher, A., Hoermann, G., Ratzinger, F., Haslacher, H., Schrezenmeier, H., et al. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0232 · Cited by 12
FoxP3+ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation
Yero, A., Shi, T., Routy, J., Tremblay, C. L., Durand, M., Costiniuk, C. T., & Jenabian, M.-A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962912 · Cited by 11
Gudi, R. R., Karumuthil‐Melethil, S., Perez, N., Li, G., & Vasu, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-48464-y · Cited by 11
Grywalska, E., Smarz-Widelska, I., Korona‐Głowniak, I., Mertowski, S., Gosik, K., Hymos, A., Ludian, J., Niedźwiedzka‐Rystwej, P., Roliński, J., & Załuska, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218001 · Cited by 10
Hybrid regulatory T cells: camouflaged architects of tumor immunity
Azimnasab-sorkhabi, P., Soltani-asl, M., Kfoury, J. R., & Ansa-Addo, E. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658576 · Cited by 9
PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity
Zhang, H., Zheng, H., Wang, Y., Chen, C., Tong, Y., Xie, S., Ma, X., Guo, L., & Lu, R. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010026 · Cited by 9
Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
Liang, Z., Chen, W., Guo, Y., Ren, Y., Tian, Y. F., Cai, W., Bao, Y., Liu, Q., Ding, P., & Li, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133883 · Cited by 9
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02416-3 · Cited by 8
Gatselis, N., Azariadis, K., Lyberopoulou, A., & Dalekos, G. N. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100126 · Cited by 8
Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer
Mohammad, S. I. S., Kareem, A. K., Vasudevan, A., Rekha, M. M., Jabir, M. S., Nayak, P. P., AlKhafaje, Z., Arora, V., Kadhum, W. R., & Chennakesavulu, K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152438 · Cited by 7
Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1
Liang, J., Tian, C., Liu, L., Zeng, X., & Zhang, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111294 · Cited by 6
Arroyo-Olarte, R. D., Pérez-Noriega, F. A., Correa-Pérez, M. F., Mejía-Muñoz, A., Terrazas, L. I., & León‐Cabrera, S. (2025) · Immunologic Research · doi:10.1007/s12026-025-09686-7 · Cited by 6
PD-1 Limits IL-2 Production and Thymic Regulatory T Cell Development
Caruso, B., Weeder, B. R., Thompson, R. F., & Moran, A. E. (2024) · ImmunoHorizons · doi:10.4049/immunohorizons.2300079 · Cited by 6
sRAGE inhibits myocardial ischemia/reperfusion injuries via regulating Treg cells
Liu, J., Zhang, J., Chang, J. K., Chen, L., Wang, H., Liu, Y., Huang, M., Zeng, X., & Guo, C. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01482-y · Cited by 5
Tang, P., Shen, X., Gao, J., Zhang, J., Feng, Y., Zhang, J., Huang, Z., & Wang, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1437207 · Cited by 5
OX40L enhances the immunogenicity of dendritic cells and inhibits tumor metastasis in mice
Zhao, L., Zhang, W., Liu, M., Jia, R., Wang, J., Wang, F., & Xu, Y. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.13037 · Cited by 5
Yero, A., Shi, T., Clain, J. A., Zghidi‐Abouzid, O., Racine, G., Costiniuk, C. T., Routy, J., Estaquier, J., & Jenabian, M.-A. (2024) · Viruses · doi:10.3390/v16101609 · Cited by 4
Yang, R., Zeng, X., Xierenguli, A., & Qu, J. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04082-4 · Cited by 4
PD1 is transcriptionally regulated by LEF1 in mature T cells
Zhao, P., Sun, L., Zhao, C., & Malik, S. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152708 · Cited by 4
Role of regulatory T-cells in the systemic inflammatory response syndrome
Khanova, M. Y., Матвеева, В. Г., Antonova, L. V., & Grigoryev, E. V. (2020) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2020-9-2-82-90 · Cited by 3
Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology
Jovanović, M., Gajović, N., Lukić, M. L., Popović, A., & Jovanović, I. (2019) · Serbian Journal of Experimental and Clinical Research · doi:10.2478/sjecr-2018-0033 · Cited by 3
Unveiling the power of plumbagin: revitalizing exhausted T cells to combat tongue cancer
Zhang, R., Jiang, Q., Guo, R., Guo, K., & Qiu, J. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03892-x · Cited by 2
Almagro, J. C., Gómez-Castellano, K., Licona‐Limón, I., Carballo‐Uicab, G., Ramírez-Villedas, F., Montes-Luna, A., González‐González, E., Godínez-Palma, S., Barrera-Saldaña, H. A., & Pérez‐Tapia, S. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1834585 · Cited by 2
Micallef, I. N., & Desai, S. H. (2025) · Medical Research Archives · doi:10.18103/mra.v13i2.6234 · Cited by 2
Adhikary, P., Chakrabarti, J. L., Mallick, S., Sun, X., Ezuma-Igwe, U., Branch, A. G., Wang, J., Braissand, N., Corbett, M. P., Kim, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.22.655586 · Cited by 2
Song, Q., Zheng, M., Li, Q., Wu, X., Lin, B., Kang, T. H., Qin, H., Kujawski, M., Pillai, R. K., Lin, J. L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.186984 · Cited by 1
Shi, Y., Tao, X., Shen, L., Yuan, Y.-C., Wang, G., Eurmsirilerd, E., Chang, R., Jia, Z., Shang, W., Yang, Y., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea3960 · Cited by 1
Improved Heat Tolerance in Heat-acclimated Mice: The Probable Role of the PD-L1 PathwayPreprint
Qiu, M., Zhou, Y., Ye, N., Guo, H., Zhou, X., Ding, X., & Li, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.20.481185 · Cited by 1
Kosmaczewska, A., Masternak, A., Kosciow, K., Ciszak, L., Usnarska‐Zubkiewicz, L., Szteblich, A., Potoczek, S., & Frydecka, I. (2019) · Research Square · doi:10.21203/rs.2.14312/v1 · Cited by 1
Metadata
- Authors
- Chen, X., Fosco, D., Kline, D. E., Meng, L., Nishi, S., Savage, P. A., & Kline, J.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Kline, Justin
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2014-08-18
- Volume
- 44
- Issue
- 9
- Pages
- 2603-2616
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- PMC
- PMC4165701
- OpenAlex
- W2113159835
- Cited by
- 107
- References
- 64
- Citations by year
- 2026: 2 · 2025: 14 · 2024: 4 · 2023: 5 · 2022: 13 · 2021: 7 · 2020: 17 · 2019: 9 · 2018: 12 · 2017: 11 · 2016: 7 · 2015: 5 · 2014: 1
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K23 CA133196)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- PD-1, PD-L1, regulatory T cells, thymic Treg development, Treg suppressive function, peripheral tolerance, PD-1 deficiency, anti-PD-1 therapy, CD4+ T cells, autoantigens
- MeSH terms
- Animals, Cell Differentiation, Immune Tolerance, Thymus Gland, Mice, Knockout, T-Lymphocytes, Regulatory, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.